OncologyOncology/Bone Tumours

Aneurysmal Bone Cyst - Calcaneus

Oncology
Intermediate
6 min
High Yield
aneurysmal bone cystfluid-fluid levelsUSP6 gene rearrangementtelangiectatic osteosarcomasecondary ABCextended curettageembolisationdenosumabcalcaneus tumourspathological fracture
6:00
Start the timer to simulate exam conditions

Aneurysmal Bone Cyst - Calcaneus

Clinical Scenario

A 20-year-old male presents with progressive right heel pain over 4 months, worse with weight-bearing. He denies any history of trauma. The pain has been gradually worsening and now limits his ability to stand for prolonged periods at work (he is a chef).

History:

  • 4-month progressive heel pain
  • Weight-bearing pain, worse with prolonged standing
  • No trauma history
  • No night pain or constitutional symptoms
  • No previous bone lesions
  • No family history of bone tumours
  • Works as a chef, on feet all day

Examination Findings:

  • Localised tenderness over lateral calcaneus
  • Mild swelling, no erythema or warmth
  • No palpable mass
  • Full ankle and subtalar range of motion
  • Pain on heel loading
  • Normal neurovascular examination
  • Mild antalgic gait (off-loads right heel)

Investigations

Laboratory Results

Imaging

Plain X-ray Right Foot (Lateral and Axial Calcaneus):

  • Expansile, eccentric lytic lesion in calcaneus body
  • Well-defined with thin cortical margins
  • 'Blown-out' appearance with egg-shell thin cortex
  • Internal septations visible
  • No matrix calcification
  • No periosteal reaction
  • No pathological fracture

MRI Right Calcaneus with Gadolinium:

  • 3.5 x 2.8 x 2.5 cm multiloculated cystic lesion
  • Multiple fluid-fluid levels (pathognomonic feature)
  • T1: Low signal
  • T2: Very high signal with internal septations
  • Thin rim enhancement with gadolinium
  • Surrounding bone marrow oedema
  • No solid enhancing components
  • Intact cortex (thinned but not breached)
  • Subtalar joint not involved

CT Chest (Staging):

  • No pulmonary metastases
  • Normal lung parenchyma

Questions & Model Answers

Q

What is your differential diagnosis for this lesion?

Q

What is the role of USP6 gene testing and how does it help in diagnosis?

Q

How would you approach the biopsy and what are your histological expectations?

Q

What are the treatment options for this aneurysmal bone cyst?

Q

What are the specific considerations for treating bone tumours in the calcaneus?

Q

What is the prognosis and follow-up protocol for this patient?


Key Teaching Points

ConceptDetail
Classic FindingFluid-fluid levels on MRI (blood sedimentation)
Critical DifferentialTelangiectatic osteosarcoma - MUST biopsy
Genetic MarkerUSP6 gene rearrangement (70% of primary ABC)
Secondary ABC30% arise within another tumour (GCT, chondroblastoma)
TreatmentExtended curettage with adjuvant + bone graft
Recurrence15-25% - repeat curettage usually successful
EmbolisationUseful adjunct or for difficult locations
PrognosisExcellent - malignant transformation extremely rare

Common Examiner Follow-up Questions

  1. "What is a secondary ABC and how do you identify it?"

    • ABC arising within a pre-existing bone tumour
    • 30% of all ABCs are secondary
    • Underlying tumours: GCT, chondroblastoma, osteoblastoma, fibrous dysplasia
    • USP6 negative (primary ABC is USP6 positive)
    • Histology shows features of underlying tumour
  2. "How do you distinguish ABC from telangiectatic osteosarcoma?"

    • Both have fluid-fluid levels
    • ABC: bland fibroblasts, low mitoses, USP6+
    • Tel-OS: atypical cells in septa, high mitoses, aggressive features
    • BIOPSY IS ESSENTIAL - never treat without histology
    • Any doubt → refer to sarcoma pathologist
  3. "What if the lesion recurs after treatment?"

    • Re-image to confirm recurrence
    • Consider re-biopsy (exclude malignancy)
    • Repeat curettage with more aggressive adjuvant
    • Consider embolisation before surgery
    • Denosumab may have role in recurrent disease
    • En bloc resection rarely needed
  4. "What is the role of denosumab in ABC?"

    • ABCs contain osteoclast-like giant cells (RANK-L mediated)
    • Denosumab is RANK-L inhibitor
    • May shrink lesion (neoadjuvant)
    • Used for recurrent or difficult-to-treat lesions
    • Limited evidence base but promising results
    • Discontinuation may lead to regrowth